Refine by
Disease Testing Articles & Analysis
106 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced release of its new line of Human Hybrid IgM Control Monoclonal Antibodies for research applications, covering a range of diseases such as CMV, HSV, MeV, MuV, RuV, and VZV.Characteristic disease state sera are serum samples derived from individuals with ...
Chronic Obstructive Pulmonary Disease (COPD) is a global health burden characterized by persistent airflow limitation and progressive lung damage. ...
Milan, Italy, September 3, 2024 — Tethis S.p.A., a pioneer in the development of a standardized liquid biopsy platform, announces a collaboration with Weill Cornell Medicine to test Tethis’ instruments for monitoring the response to curative treatment in patients with early-stage breast cancer. The scientists will collect blood from the patients and will measure the ...
These models have been specifically designed to enable research on different types of diabetes including type 1, type 2, and gestational diabetes, providing valuable insights into disease mechanisms and potential treatment options. Diabetes mellitus is a chronic, systemic, metabolic disease caused by the long-term combination of genetic factors and ...
Tempus, a leader in artificial intelligence and precision medicine, today announced the clinical launch of its minimal residual disease (MRD) test portfolio, including Tempus’ xM test and the xM (NeXT Personal® Dx) test by Personalis. ...
ByTempus
Cognitive behavioral tests have wide applications in understanding neurodegenerative diseases and non-neurological disorders that often lead to cognitive dysfunction. These conditions pose significant challenges to patients' health and well-being. To delve into these diseases, rodents are commonly employed as research subjects in ...
Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. ...
With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery. ...
About Castle Biosciences Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors. Castle’s current portfolio consists of tests for skin ...
After airborne infection with Mycobacterium Tuberculosis, the new model system aims to show the disease-specific phenotype of “frustrated” phagocytosis, air-blood barrier damage, activated lymph node tissue and granuloma formation and maintenance. The disease model will then be used to test screening of TB vaccine candidates. ...
XPhyto is investigating the potential application of one or more of its ODF biosensor screening tests for oral inflammation to detect buprenorphine-related dental problems. ...
The new team members bring skill sets and experience that will support the commercial launch of its blood testing ecosystem, which reimagines blood testing from collection to sample preparation to analysis, to better meet the needs of the modern clinician and consumer. ...
Infectious disease testing (including sepsis) is one of the fastest growing molecular diagnostic segments representing approximately $2 billion globally per year. ...
Fully aware of this, CD Formulation, a New York-based CRO company reputed for high-quality drug pre-formulation services, announced earlier this month to have launched long-term accelerated shelf-life testing for drug developers and pharmaceutical companies worldwide. With the advance of controlled storage testing facilities, now accelerated shelf-life ...
Optina Diagnostics is developing its awAIr™ cerebral amyloid status test to facilitate the reliable and early detection of Alzheimer’s disease. ...
Abingdon Health plc (AIM: ABDX), a leading international developer and manufacturer of high quality and effective rapid tests, announces the launch of its new B2C e-commerce website, abingdonsimplytest.com. ...
Alveo Technologies, a leader in developing novel technologies that enable real-time, low-cost, at-home molecular detection of infectious disease, today announced that Fran Soistman has joined the company’s Scientific Advisory Board (SAB). ...
Theoretically, the 50% cytotoxic concentration (CC50) is the concentration of test compound required to reduce cell viability by 50%. Cytotoxicity of test compounds is best determined simultaneously with uninfected cells to obtain a 50% cytotoxic concentration (CC50) value. Cytotoxicity tests use proportionally increasing concentrations of the ...
“MatTek has really pioneered the field of lab-grown tissues for preclinical testing, and we’ve had great success in developing multiple organ systems that have been shown to produce results much closer to live human responses than traditional animal testing,” said Kevin Causey, vice president of business development for MatTek. ...
Cleveland Diagnostics, Inc., a clinical-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, announced today that its prostate cancer test, IsoPSA, has been added to the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer Early Detection (version 1.2022). ...